Semaglutide is effectively tolerated without having possibility of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse effects. A substantial population impacted with COVID-19 an infection have been diabetic; consequently utilization of semaglutide in diabetic issues along with CV people can be greatly supportive in protecting overall health treatment system for https://rogeri554ufp6.59bloggers.com/profile